An integrated dose-finding tool for phase I trials in oncology
- 1 November 2015
- journal article
- Published by Elsevier BV in Contemporary Clinical Trials
- Vol. 45, 426-434
- https://doi.org/10.1016/j.cct.2015.09.019
Abstract
No abstract availableKeywords
Funding Information
- NIH (2R01 CA132897-06)
This publication has 17 references indexed in Scilit:
- Phase I Trial Improvement: A Question of Patient Selection, Trial Design, or Both?Journal of Clinical Oncology, 2014
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Adaptive clinical trial designs for phase I cancer studiesStatistics Surveys, 2014
- Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I TrialsJournal of Clinical Oncology, 2013
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2011
- A modified toxicity probability interval method for dose-finding trialsClinical Trials, 2010
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI Journal of the National Cancer Institute, 2009
- Translation of Innovative Designs Into Phase I TrialsJournal of Clinical Oncology, 2007
- Dose-finding in phase I clinical trials based on toxicity probability intervalsClinical Trials, 2007
- Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.International Journal of Gynecologic Cancer, 2003